The groundbreaking rise of Viagra has long been a benchmark of pharmaceutical success, but its legacy within the broader market now raises questions about long-term yields . Alternative versions are undercutting patent protection , leading to anxieties that investing in companies significantly dependent to Viagra's previous influence could be a spe